Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Increases By 498.5%

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a large increase in short interest in September. As of September 15th, there was short interest totaling 80,200 shares, an increase of 498.5% from the August 31st total of 13,400 shares. Based on an average daily trading volume, of 1,210,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the shares of the stock are sold short. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,210,000 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC purchased a new stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 37,450 shares of the company’s stock, valued at approximately $36,000. HighTower Advisors LLC owned approximately 0.09% of Barinthus Biotherapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Stock Performance

Shares of Barinthus Biotherapeutics stock opened at $1.42 on Friday. The firm has a market cap of $57.82 million, a P/E ratio of -0.82 and a beta of -0.71. The firm’s 50-day simple moving average is $1.25 and its 200-day simple moving average is $1.06. Barinthus Biotherapeutics has a twelve month low of $0.64 and a twelve month high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.23). On average, equities analysts forecast that Barinthus Biotherapeutics will post -1.38 earnings per share for the current fiscal year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.